Asthma Treatment Program (Adult)
The Adult Clinic at National Jewish Health is a comprehensive, outpatient program that offers patients and their families a multidisciplinary approach to the evaluation and management of their asthma. Our team of asthma specialists includes physicians who are leaders in allergy, immunology and pulmonary medicine. Additional specialists on the team who contribute in assessment and treatment are respiratory nurses, respiratory therapists, and physical and occupational therapists.
Our physicians develop an individualized plan of care that reflects each patient's need for physical assessment, respiratory therapy, medications, physical and occupational therapy, nutritional support and education.
Length of Stay
Patients who live outside the Denver area are scheduled for a 7-10 day visit, depending on each patient's needs. In most cases, a weekend stay is required. Patients will have three visits with their treating physician as well as diagnostic testing, health education, specialty physician consultations and rehabilitation treatment. The clinic staff will provide them with a written schedule of appointments every day.
Patients who have difficult to manage asthma or those who have not succeeded in an outpatient setting may require a more intensive evaluation and treatment program. The enhanced program typically lasts ten days and is specifically tailored to the individual patient. Because patients in this program are often more severely ill, additional assistance is provided based on the needs of the patient.
Related Programs
- The Cohen Family Asthma Institute
- Division of Allergy and Clinical Immunology
- Division of Environmental and Occupational Health Sciences (Occupational asthma)
- Division of Pulmonary and Critical Care Medicine
- Exercise Tolerance Center
- Interventional Pulmonology Program
- Rehabilitation Services
Doctors
-
Rafeul Alam, MD, PhD
-
Ron Balkissoon, MD, MSc, DIH, FRCPC
-
David A. Beuther, MD, PhD, FCCP
-
Jordan Bull, PA-C
-
Gregory P. Downey, MD, FRCPC
-
Anthony N. Gerber, MD, PhD
-
Magdalena Maria Gorska, MD, PhD
-
Vamsi P. Guntur, MD, MSc
-
Flavia Cecilia Lega Hoyte, MD
-
Rohit K. Katial, MD
-
Steven E. Lommatzsch, MD
-
Laurie A. Manka, MD
-
James K. O'Brien, MD, FACP, FCCP
-
Kanao Otsu, MD, MPH
-
Eileen Wang, MD, MPH
-
Michael E. Wechsler, MD, MMSc
-
Catherine Wittman, MD
Clinical Trials
Idiopathic Pulmonary Fibrosis (IPF) & GERD
The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI).
Learn More- ADRN-12/LEADS (Longitudinal Endotyping of Atopic Dermatitis Through Transcriptomic Skin Analysis)
- Atopic Dermatitis & Skin Infections
- BBT-877: Possible Treatment for Idiopathic Pulmonary Fibrosis
- BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis
- Biomarkers & Hypersensitivity Pneumonitis Progression
- Blood Test to Help Identify Cancer
- Can Pembrolizumab (MK3475) with SBRT Treatment Stop or Slow Non-Small Cell Lung Cancer?
- CHARM Study for Asthma
- Creating Asthma Measurements through the MORRE Study
- Effects of Pregnancy for Cystic Fibrosis Patients
- Extensive Stage Small Cell Lung Cancer Combination Treatment
- Healthy Adults Needed for Beryllium Disease Study
- Healthy People Needed for Sarcoidosis Research
- Identifying Characteristics and Patterns of Asthma
- ILD & Early Rheumatoid Arthritis
- Immune Pathways & Development of Sarcoidosis
- Improving Treatment for IPF
- Investigational Gene Therapy for Adults with CF
- Link Between Rheumatoid Arthritis & Lung Disease
- Lung Cancer & COVID Infection
- Lung Injury from Military Deployment
- Mineral Dust & Lung Disease
- MyAI Registry for People with Adrenal Insufficiency
- New Trial Medication for Pulmonary Arterial Hypertension
- NICE-CF: Colon Cancer Screening for adults with Cystic Fibrosis
- OCEAN Study for EGPA
- Potential New Treatment for Metastatic Lung Cancer
- Potential New Treatment for Metastatic Lung Cancer
- PRA023 for Systemic Sclerosis with Interstitial Lung Disease
- Predict and Prevent Lung Disease
- Predicting ILD from Hypersensitivity Pneumonitis
- Pulmonary Arterial Hypertension & increased dose of Opsumit
- Pulmonary Fibrosis & Genetic Factors
- RESOLVE-Lung Study for Pulmonary Sarcoidosis
- Silicosis Registry
- Skin Reactions to Cancer Immunotherapy
- Skin, Airway & Esophageal Epithelial Barriers in Youth
- SUNBEAM: Studying Allergy Development in Babies
- SUNRISE Trial for Oral Steroid Dependent Asthma
- Treating Deployment-Related Asthma with Supplements
- Understanding Allergy Development in Infants
- Understanding Reproductive Health Concerns in Men with CF
- Understanding Skin Problems from Eczema and Food Allergies
- XTMAB-16: A New Drug to Reduce Steroid Use in Sarcoidosis
Reasons to Choose National Jewish Health
- The leading respiratory hospital in the nation and the only one devoted fully to the treatment of respiratory and related illnesses
- Ranked #1 or #2 in Pulmonology by U.S. News & World Report for 26 consecutive years
- Ranked in the top 5% of hospitals in the nation by HCAHPS
- Physicians consistently recognized among the best in the nation by multiple services, including Best Doctors in America and Castle Connolly
- Among the top 6% of organizations funded for research by the NIH, providing patients access to hundreds of active clinical trials
- 124-year history of focus on care, research and education serving patients from around the world with lung, heart, immune and related disorders
Changing Gears and Adding Years: A Hot Rodder’s Recovery Story
Changing Gears and Adding Years: A Hot Rodder’s Recovery Story
Read More